Adaptive immunity is an immune response that can be identified and initiated against perinecrotic tumor cells, which exhibits the greatest advantage in specificity and durability.[27] In our study, NP+PD‐1 (+) induced 3.20% CD4+ helper T cells and 2.58% CD8+ cytotoxic T lymphocytes infiltration in distant tumors, gated by CD3+ cells, which were 6.5‐fold and 7.4‐fold higher than PBS (−) group, respectively (Figure 6b,c; Figure S21, Supporting Information). The gene discussed is PDCD1; the disease is neoplasm.